- Home
- XTKG vs MEIP Comparison
XTKG vs MEIP Comparison
Compare XTKG & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- MEIP
- Stock Information
- Founded
- XTKG 1997
- MEIP 2000
- Country
- XTKG Singapore
- MEIP United States
- Employees
- XTKG N/A
- MEIP N/A
- Industry
- XTKG
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- MEIP Health Care
- Exchange
- XTKG NYSE
- MEIP Nasdaq
- Market Cap
- XTKG 16.3M
- MEIP 13.3M
- IPO Year
- XTKG 2019
- MEIP 2003
- Fundamental
- Price
- XTKG $1.55
- MEIP $2.53
- Analyst Decision
- XTKG
- MEIP Hold
- Analyst Count
- XTKG 0
- MEIP 1
- Target Price
- XTKG N/A
- MEIP N/A
- AVG Volume (30 Days)
- XTKG 106.9K
- MEIP 21.5K
- Earning Date
- XTKG 07-07-2025
- MEIP 05-13-2025
- Dividend Yield
- XTKG N/A
- MEIP N/A
- EPS Growth
- XTKG N/A
- MEIP N/A
- EPS
- XTKG N/A
- MEIP N/A
- Revenue
- XTKG $11,611,442.00
- MEIP N/A
- Revenue This Year
- XTKG N/A
- MEIP N/A
- Revenue Next Year
- XTKG N/A
- MEIP N/A
- P/E Ratio
- XTKG N/A
- MEIP N/A
- Revenue Growth
- XTKG N/A
- MEIP 33.76
- 52 Week Low
- XTKG $0.53
- MEIP $1.46
- 52 Week High
- XTKG $11.60
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- XTKG 49.51
- MEIP 78.43
- Support Level
- XTKG $1.36
- MEIP $2.21
- Resistance Level
- XTKG $2.24
- MEIP $2.95
- Average True Range (ATR)
- XTKG 0.23
- MEIP 0.15
- MACD
- XTKG -0.03
- MEIP 0.05
- Stochastic Oscillator
- XTKG 22.22
- MEIP 81.48
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.